Researchers find a marked increase in tetracycline-resistant gonorrhea and increased colonization with tetracycline-resistant Staphylococcus aureus following the rollout of doxyPEP.
Among patients prescribed doxycycline post-exposure prophylaxis, cases of syphilis, chlamydia, and gonorrhea fell by 86.4%. 89.7%, and 54.7%, respectively.
The rate of gonorrhea cases across Europe rose by 31% in 2023 compared with 2022, and is up 321% since 2014.
Two studies in California found significant reductions in chlamydia and syphilis in the year after doxycycline post-exposure prophylaxis guidelines were released.
Hepatitis A virus and vaccinia virus showed evidence for sexual transmission but no evidence for detection in the semen.
The number of STIs declined almost 2% from 2022 to 2023, a sign that the dramatic rise in STIs since 2011 might be leveling off.
The infections were caused by Trichophyton mentagrophytes type VII (TMVII), a sexually transmitted fungus that causes ringworm.
The report contains temporary recommendations, such as regulatory consideration of mpox vaccine approval and planning for vaccine campaigns.
Lentocilin is the second drug to get FDA clearance for temporary import as rising syphilis infections outstrip treatment supply, including for newborns.
The fastest-growing diagnoses were for syphilis, gonorrhea, and HIV/AIDS.
